# OnCo record paper-brentuximab-relapsed-salcl-phase-2-jco-2012 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-brentuximab-relapsed-salcl-phase-2-jco-2012/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-brentuximab-relapsed-salcl-phase-2-jco-2012" ;
  schema:name "Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study"@en ;
  schema:alternateName "Pro 2012"@en, "SG035-0004"@en ;
  schema:description "The study in which brentuximab vedotin made relapsed systemic anaplastic large cell lymphoma shrink in 86 per cent of patients and disappear on scans in 57 per cent."@en ;
  schema:url <https://onco.cc/key-papers/paper-brentuximab-relapsed-salcl-phase-2-jco-2012/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.2011.38.0402>, <https://pubmed.ncbi.nlm.nih.gov/22614995/>, <https://europepmc.org/article/MED/22614995> ;
  onco:tag "lymphoma-evidence-entities" ;
  schema:sameAs <https://doi.org/10.1200/JCO.2011.38.0402> ;
  schema:datePublished "2012"^^xsd:gYear ;
  schema:author "Pro B, Advani R, Brice P, et al." ;
  onco:cancers <https://onco.cc/cancers/alk-positive-anaplastic-large-cell-lymphoma/>, <https://onco.cc/cancers/alk-negative-anaplastic-large-cell-lymphoma/> ;
  onco:targets <https://onco.cc/targets/cd30/> ;
  onco:drugs <https://onco.cc/drugs/brentuximab-vedotin/> ;
  onco:trials <https://onco.cc/trials/brentuximab-salcl-phase-2/> .